The U.S. Food and Drug Administration (FDA) on Friday approved Biogen and Sage Therapeutics oral pill to treat postpartum depression (PPD) in…
ChemRobotics Pvt. Ltd. © 2023, All Rights Reserved.
Designed and Developed by Ample eBusiness
Tag:
Biogen
-
-
Summary : –Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer’s therapy Aduhelm, handing over…
-
Global MarketPharma Science & Research
Lilly, Roche Push Back Against CMS Draft Guidance on Aduhelm
by adminby adminSummary The U.S. Centers for Medicare & Medicaid Services (CMS) just completed the open comment period for their draft national coverage decision…
-
BiogenGlobal Market
Biogen Officially Weighs in On Medicare Draft Guidance for Aduhelm
by adminby adminSummary – In mid-January, the Centers for Medicare & Medicaid Services (CMS) issued a draft national coverage decision for Biogen’s Alzheimer’s drug…
-
AgrochemicalsBiogenGlobal Market
Biogen’s Aduhelm Grabs the Spotlight at User Fee Renewals Hearing
by adminby adminSummary – The House Energy and Commerce Committee’s health panel met to discuss renewing user fee agreements used to fund the U.S.…
-
AgrochemicalsGlobal Market
Biogen Departure Train Chugs on as Two Board Members Exit
by adminby adminSummary : One week after Johnna Rossell departed Biogen for Enzyvant, the embattled company announced that two members of its board of…
-
AgrochemicalsGlobal Market
Biogen Recoups Much-Needed $2.3B with Sale of Samsung Bioepis Stake
by adminby adminSynopsis : Biogen is selling its nearly 50% stake in South Korea-based Samsung Bioepis for $2.3 billion. The move will provide Biogen…
-
CompaniesEli Lilly
JPM 2022: Eli Lilly gears up for Alzheimer’s-diabetes juggling act as 2 key FDA decisions loom
by adminby adminSummary : On the brink of two major approvals this year, Eli Lilly is laser-focused on diabetes and dementia. One market is…
-
AgrochemicalsGlobal Market
Biogen, Eisai face Down Another Aduhelm Refusal—this Time from Japanese Regulators
by adminby adminSynopsis: After a special meeting, the Japanese drug reviewers ruled that existing data didn’t support an approval and are therefore seeking additional…
-
Synopsis: The EMA’s human medicines committee has said it cannot approve Biogen and Eisai’s Alzheimer’s disease therapy Aduhelm, saying it was unconvinced…
Newer Posts